NCT06709521

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

CompletedPHASE4INTERVENTIONAL

Trial Details

Start: 2025-02-12Est. Completion: 2026-07-02

Enrollment target: 161 participants

Locations

Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States
Torrance Memorial Medical Center, Torrance, California, United States
Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States
Corewell Health - Infectious Disease, Royal Oak, Michigan, United States
Duke University Hospital - Infectious Diseases, Durham, North Carolina, United States
East Carolina University - Infectious Diseases and Tropical/Travel Medicine Clinic, Greenville, North Carolina, United States
University of Cincinnati College of Medicine - Division of Infectious Diseases, Cincinnati, Ohio, United States
Oregon Health and Science University - Adult Infectious Diseases Clinic, Portland, Oregon, United States
University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh, Pennsylvania, United States
Carilion Roanoke Memorial Hospital, Roanoke, Virginia, United States

Other microbiome trials you might be interested in

VE303 for Prevention of Recurrent Clostridioides Difficile InfectionPhase 3Recruiting

Clostridium DifficileClostridium Difficile InfectionsClostridium Difficile Infection RecurrenceClostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceCDIC. Diff InfectionRecurrent Clostridium Difficile InfectionC.Difficile DiarrheaDiarrhea Infectious

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (…

Huntsville, United StatesEst. completion Jun 2027

View Trial →

Oral Lactobacillus Crispatus Lc-G22 as Adjunctive Therapy for Vulvovaginal Candidiasis

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.